Table 3.

Most common adverse events occurring in ≥ 30% of patients receiving volasertib and azacitidine in Studies 1 (Part 1) and 2

n (%)	Study 1 Part 1 (n = 13)					Study 2 (n = 5)
	All	G1	G2	G3	G4	All	G1	G2	G3	G4
Injection site reaction	0	0	0	0	0	5 (100)	4 (80)	1 (20)	0	0
Thrombocytopenia	10 (77)	0	0	2 (15)	8 (62)	2 (40)	0	0	2 (40)	0
Neutropenia	7 (54)	0	1 (8)	0	6 (46)	1 (20)	0	0	0	1 (20)
Diarrhea	6 (46)	5 (39)	0	1 (8)	0	2 (40)	2 (40)	0	0	0
Decreased appetite	6 (46)	4 (31)	2 (15)	0	0	1 (20)	0	1 (20)	0	0
Rash	6 (46)	5 (39)	1 (8)	0	0	0	0	0	0	0
Febrile neutropenia	2 (15)	0	0	2 (15)	0	2 (40)	0	0	2 (40)	0
Pneumonia	3 (23)	0	1 (8)	2 (15)	0	2 (40)	0	1 (20	1 (20)	0
Pyrexia	3 (23)	3 (23)	0	0	0	2 (40)	2 (40)	0	0	0
Pharyngitis	0	0	0	0	0	2 (40)	2 (40)	0	0	0
White blood cell count decreased	0	0	0	0	0	2 (40)	0	0	1 (20)	1 (20)
Hypersensitivity	0	0	0	0	0	2 (40)	1 (20)	1 (20)	0	0
Fatigue	5 (39)	2 (15)	3 (23)	0	0	1 (20)	1 (20)	0	0	0
Constipation	5 (39)	4 (31)	0	1 (8)	0	1 (20)	0	1 (20)	0	0
Cough	5 (39)	5 (39)	0	0	0	0	0	0	0	0
Nausea	5 (38)	4 (31)	1 (8)	0	0	0	0	0	0	0
Blood creatinine increased	4 (31)	2 (15)	2 (15)	0	0	0	1 (20)	1 (20)	0	0
Anemia	4 (31)	0	3 (23)	1 (8)	0	0	1 (20)	0	0	1 (20)
Vomiting	4 (31)	3 (23)	1 (8)	0	0	0	0	0	0	0
Erythema	4 (31)	3 (23)	1 (8)	0	0	0	0	0	0	0
Alopecia	4 (31)	4 (31)	0	0	0	0	0	0	0	0

G grade